316 related articles for article (PubMed ID: 30793413)
21. Microtubules: A Key to Understand and Correct Neuronal Defects in CDKL5 Deficiency Disorder?
Barbiero I; De Rosa R; Kilstrup-Nielsen C
Int J Mol Sci; 2019 Aug; 20(17):. PubMed ID: 31438497
[TBL] [Abstract][Full Text] [Related]
22. HDAC4: a key factor underlying brain developmental alterations in CDKL5 disorder.
Trazzi S; Fuchs C; Viggiano R; De Franceschi M; Valli E; Jedynak P; Hansen FK; Perini G; Rimondini R; Kurz T; Bartesaghi R; Ciani E
Hum Mol Genet; 2016 Sep; 25(18):3887-3907. PubMed ID: 27466189
[TBL] [Abstract][Full Text] [Related]
23. Aged heterozygous Cdkl5 mutant mice exhibit spontaneous epileptic spasms.
Mulcahey PJ; Tang S; Takano H; White A; Davila Portillo DR; Kane OM; Marsh ED; Zhou Z; Coulter DA
Exp Neurol; 2020 Oct; 332():113388. PubMed ID: 32585155
[TBL] [Abstract][Full Text] [Related]
24. CDKL5 Deficiency Augments Inhibitory Input into the Dentate Gyrus That Can Be Reversed by Deep Brain Stimulation.
Hao S; Wang Q; Tang B; Wu Z; Yang T; Tang J
J Neurosci; 2021 Oct; 41(43):9031-9046. PubMed ID: 34544833
[TBL] [Abstract][Full Text] [Related]
25. Chemical genetic identification of CDKL5 substrates reveals its role in neuronal microtubule dynamics.
Baltussen LL; Negraes PD; Silvestre M; Claxton S; Moeskops M; Christodoulou E; Flynn HR; Snijders AP; Muotri AR; Ultanir SK
EMBO J; 2018 Dec; 37(24):. PubMed ID: 30266824
[TBL] [Abstract][Full Text] [Related]
26. Altered NMDAR signaling underlies autistic-like features in mouse models of CDKL5 deficiency disorder.
Tang S; Terzic B; Wang IJ; Sarmiento N; Sizov K; Cui Y; Takano H; Marsh ED; Zhou Z; Coulter DA
Nat Commun; 2019 Jun; 10(1):2655. PubMed ID: 31201320
[TBL] [Abstract][Full Text] [Related]
27. Temporal manipulation of Cdkl5 reveals essential postdevelopmental functions and reversible CDKL5 deficiency disorder-related deficits.
Terzic B; Davatolhagh MF; Ho Y; Tang S; Liu YT; Xia Z; Cui Y; Fuccillo MV; Zhou Z
J Clin Invest; 2021 Oct; 131(20):. PubMed ID: 34651584
[TBL] [Abstract][Full Text] [Related]
28. CDKL5 deficiency disorder: molecular insights and mechanisms of pathogenicity to fast-track therapeutic development.
Van Bergen NJ; Massey S; Quigley A; Rollo B; Harris AR; Kapsa RMI; Christodoulou J
Biochem Soc Trans; 2022 Aug; 50(4):1207-1224. PubMed ID: 35997111
[TBL] [Abstract][Full Text] [Related]
29. Dopaminergic loss of cyclin-dependent kinase-like 5 recapitulates methylphenidate-remediable hyperlocomotion in mouse model of CDKL5 deficiency disorder.
Jhang CL; Lee HY; Chen JC; Liao W
Hum Mol Genet; 2020 Aug; 29(14):2408-2419. PubMed ID: 32588892
[TBL] [Abstract][Full Text] [Related]
30. Molecular and Synaptic Bases of CDKL5 Disorder.
Zhu YC; Xiong ZQ
Dev Neurobiol; 2019 Jan; 79(1):8-19. PubMed ID: 30246934
[TBL] [Abstract][Full Text] [Related]
31. Pregnenolone and pregnenolone-methyl-ether rescue neuronal defects caused by dysfunctional CLIP170 in a neuronal model of CDKL5 Deficiency Disorder.
Barbiero I; Peroni D; Siniscalchi P; Rusconi L; Tramarin M; De Rosa R; Motta P; Bianchi M; Kilstrup-Nielsen C
Neuropharmacology; 2020 Mar; 164():107897. PubMed ID: 31794725
[TBL] [Abstract][Full Text] [Related]
32. Voluntary Running Improves Behavioral and Structural Abnormalities in a Mouse Model of CDKL5 Deficiency Disorder.
Mottolese N; Uguagliati B; Tassinari M; Cerchier CB; Loi M; Candini G; Rimondini R; Medici G; Trazzi S; Ciani E
Biomolecules; 2023 Sep; 13(9):. PubMed ID: 37759796
[TBL] [Abstract][Full Text] [Related]
33. CDKL5, a novel MYCN-repressed gene, blocks cell cycle and promotes differentiation of neuronal cells.
Valli E; Trazzi S; Fuchs C; Erriquez D; Bartesaghi R; Perini G; Ciani E
Biochim Biophys Acta; 2012; 1819(11-12):1173-85. PubMed ID: 22921766
[TBL] [Abstract][Full Text] [Related]
34. X-linked cellular mosaicism underlies age-dependent occurrence of seizure-like events in mouse models of CDKL5 deficiency disorder.
Terzic B; Cui Y; Edmondson AC; Tang S; Sarmiento N; Zaitseva D; Marsh ED; Coulter DA; Zhou Z
Neurobiol Dis; 2021 Jan; 148():105176. PubMed ID: 33197557
[TBL] [Abstract][Full Text] [Related]
35. Aminoglycoside drugs induce efficient read-through of
Fazzari M; Frasca A; Bifari F; Landsberger N
RNA Biol; 2019 Oct; 16(10):1414-1423. PubMed ID: 31232219
[TBL] [Abstract][Full Text] [Related]
36. AMPA Receptor Dysregulation and Therapeutic Interventions in a Mouse Model of CDKL5 Deficiency Disorder.
Yennawar M; White RS; Jensen FE
J Neurosci; 2019 Jun; 39(24):4814-4828. PubMed ID: 30952813
[TBL] [Abstract][Full Text] [Related]
37. CDKL5 kinase controls transcription-coupled responses to DNA damage.
Khanam T; Muñoz I; Weiland F; Carroll T; Morgan M; Borsos BN; Pantazi V; Slean M; Novak M; Toth R; Appleton P; Pankotai T; Zhou H; Rouse J
EMBO J; 2021 Dec; 40(23):e108271. PubMed ID: 34605059
[TBL] [Abstract][Full Text] [Related]
38. CDKL5-mediated developmental tuning of neuronal excitability and concomitant regulation of transcriptome.
Liao W; Lee KZ
Hum Mol Genet; 2023 Nov; 32(23):3276-3298. PubMed ID: 37688574
[TBL] [Abstract][Full Text] [Related]
39. Smad3 deficiency increases cortical and hippocampal neuronal loss following traumatic brain injury.
Villapol S; Wang Y; Adams M; Symes AJ
Exp Neurol; 2013 Dec; 250():353-65. PubMed ID: 24120438
[TBL] [Abstract][Full Text] [Related]
40. Cannabidiol attenuates seizure susceptibility and behavioural deficits in adult CDKL5
Li X; Yennawar M; Wiest A; O'Brien WT; Babrowicz B; White RS; Talos DM; Jensen FE
Eur J Neurosci; 2024 Jun; 59(12):3337-3352. PubMed ID: 38654472
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
